Gibbons Lab
Sort
New ISB research shows that different patient responses to statins can be explained by the variation in the human microbiome. The findings were published in the journal Med, and suggest that microbiome monitoring could be used to help optimize personalized statin treatments.
In the final ISB-Town Hall Seattle Science Series of 2021, ISB Assistant Professor Dr. Sean Gibbons sat down with UCSD Professor Dr. Jack Gilbert, and the two microbiome experts discussed past research, exciting science happening today, promising products and therapies on the horizon, and much more.
The 2021 ISB Virtual Microbiome Series highlighted recent advances toward understanding general patterns of commensal population genomic variation within the human gut, how fine-scale commensal genomic variation is influenced by host phenotypic variation, and whether or not commensal genomic variation has an impact on human health and disease.
The strongest associations with weight loss success or failure – independent of BMI – are found in the genetic capacity of the gut microbiome. These new findings open the door to diagnostic tests that can identify people likely to lose weight with healthy lifestyle changes and those who might need more drastic interventions.
In ISB’s first-ever Research Roundtable event, Assistant Professor Dr. Sean Gibbons delivered a presentation titled “Gut-Check: Personalized Nutrition and Your Microbiome.” His talk covered a lot of ground, including recently published research showing how the health of our microbiomes can predict longevity, and how we can build and maintain a healthy gut microbiome.
ISB’s research into the aging microbiome was featured in a story published by Anahad O’Connor for The New York Times titled “A Changing Gut Microbiome May Predict How Well You Age.” The research featured was published in Nature Metabolism by Drs. Tomasz Wilmanksi, Noa Rappaport, Sean Gibbons and Nathan Price.